Clinical Trial

Medium-term Results of the LPS™ System for Segmental Resection of the Distal Femur, a Multicenter Retrospective Study (RESIF)

Study acronym: RESIF
Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated April 15, 2025 (before its estimated July 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The reconstruction of the distal femur using modular systems has become increasingly popular over the years, surpassing primary arthrodesis or amputation. Despite the significant advantages of using megaprostheses, complications are not uncommon. Although the Limb Preservation System™ (LPS™, DePuy Synthes; Warsaw, USA) is one of the most widely used megaprostheses in the French market, there is currently no national evaluation of this system, and only two studies have been conducted worldwide. The aim of our study is to present the mid-term survival rates of the LPS™ implant in order to answer three main questions: 1. What are the overall outcomes of the LPS™ system in distal femur replacement? 2. What factors are associated with a reduced survival rate of the implant? 3. What is the cumulative risk of complications according to Henderson's classification? The secondary objective is to analyze the occurrence of specific failures, providing insights for potential improvements in the design and use of the LPS™ implant.
Trial Details
NCT Number NCT06928948
Lead Sponsor University Hospital, Brest
Conditions Prosthesis Failure
Enrollment 77 participants
Start Date 2024-11-01
Primary Completion 2025-07-31 (estimated)
Study Completion 2025-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-15